The core of a BRET2-based intracellular protease sensor is a single engineered fusion protein. You design a construct that places a bioluminescent donor (Renilla luciferase, Rluc) and a fluorescent acceptor (GFP2) on either side of a specific protease cleavage site—such as the tetrapeptide DEVD for caspase-3. When the protease is inactive, intramolecular energy transfer yields a high BRET2 signal; upon activation and cleavage, the signal drops measurably, providing a real‑time, quantitative readout of enzymatic activity.
A BRET2 protease assay fuses Rluc and GFP2 with a target-specific cleavage sequence between them. Cleavage physically separates the donor-acceptor pair, causing a dose-dependent decrease in the 515/410 nm emission ratio that directly reports on caspase-3 activation inside living cells.
Engineering the Cleavable Fusion Protein
The design begins with a clear understanding of the protease’s preferred substrate. The goal is to create a single polypeptide chain that pairs the energy transfer partners around a labile linker.
Choosing the Cleavage Site Sequence
The linker must contain a consensus amino acid sequence recognized and cut by the target protease. For caspase-3, the canonical sequence is DEVD (Asp-Glu-Val-Asp).
This short tetrapeptide is cloned into the region between the donor and acceptor domains. The sequence must be both highly selective for the protease of interest and efficiently cleaved to generate a robust signal change.
Placing the Donor and Acceptor Domains
The two BRET2 partners are arranged to maximize energy transfer in the intact state. The construct is typically a linear fusion: GFP2–linker–Rluc or Rluc–linker–GFP2.
The choice of N‑ to C‑terminal order is driven by expression, folding, and steric considerations. In the classic caspase‑3 sensor, a GFP2-DEVD-Rluc arrangement ensures efficient basal BRET and exposes the linker to the protease without steric hindrance.
How BRET2 Reports Protease Activity
The signal mechanism converts a biochemical cleavage event into a measurable optical change, without requiring any additional external reagents.
Basal State: High BRET2 Signal
In the absence of active protease, Rluc and GFP2 are held in immediate proximity on the same molecule. When the coelenterazine substrate is added, Rluc emits light, and a large fraction of that energy is transferred non‑radiatively to GFP2.
This results in a high BRET2 ratio (acceptor emission at 515 nm divided by donor emission at 410 nm). The cell or lysate emits a predominantly green‑shifted luminescence signal.
Cleavage Event: Loss of Proximity, Decreased Signal
When caspase-3 is activated—for example, during drug‑induced apoptosis—it recognizes and cuts the DEVD site. This breaks the physical tether between Rluc and GFP2.
The separated donor can no longer efficiently transfer energy to the acceptor. The BRET2 ratio drops in a dose‑dependent manner, directly correlating with the amount of active caspase-3.
Ensuring Specificity and Validating the Assay
A high‑quality sensor must be validated to rule out false positives and confirm that the observed signal change is truly protease‑specific.
Using Selective Protease Inhibitors
The most straightforward control is a specific chemical inhibitor. For caspase‑3, inhibitors such as Caspase-3 Inhibitor I (e.g., Ac-DEVD-CHO) can be co‑applied with the apoptotic stimulus.
When the inhibitor is present, the DEVD site remains uncleaved, and the BRET2 ratio stays at its basal high level. This confirms that the signal decrease is due to genuine caspase‑3 activity, not general proteolysis or cell death artifacts.
Designing Non‑Cleavable Control Constructs
A parallel negative control is a non‑cleavable fusion protein in which the cleavage site is mutated or deleted (e.g., a GFP2-Rluc fusion with no linker cleavage sequence). This construct should maintain a stable BRET2 signal under all treatment conditions.
If the experimental construct shows a drop while the non‑cleavable control remains steady, the assay is validated as cleavage‑dependent. This internal check is essential for distinguishing signal change from technical issues like protein degradation or aggregation.
Understanding the Trade‑offs and Critical Considerations
Every assay design involves compromises. Here are the key factors that can limit performance or lead to misinterpretation.
- Linker accessibility: A bulky donor‑acceptor pair may mask the cleavage site. If the DEVD sequence is sterically buried, the apparent protease activity will be underestimated or absent, even if the enzyme is fully active.
- Expression levels: High overexpression of the sensor can saturate the cleavage machinery or cause aggregation, leading to abnormal basal BRET ratios. Titration of plasmid DNA and selection of stable clones are often required.
- Signal‑to‑noise in un‑cleaved state: If the basal BRET2 ratio is already low due to poor donor‑acceptor coupling, the dynamic range upon cleavage will be compressed. Optimizing linker length and flexibility is crucial.
- Specificity beyond the canonical sequence: A short peptide like DEVD can be recognized by other caspases or proteases with similar specificity. Multi‑site mutagenesis or parallel testing with alternative inhibitors can help deconvolute contributions.
Making the Right Choice for Your Goal
The optimal design path depends on whether your primary need is pathway‑specific detection, screening throughput, or absolute quantification.
- If your primary focus is monitoring apoptosis in real time: Use the GFP2-DEVD-Rluc construct with a broad‑spectrum caspase inducer. Validate with Caspase-3 Inhibitor I and include a non‑cleavable GFP2-Rluc control to confirm that the signal drop is cleavage‑dependent.
- If your primary focus is high‑throughput screening of pro‑apoptotic compounds: Design the assay in a homogeneous, mix‑and‑measure format using stably transfected cells. The intrinsic ratiometric nature of BRET2 removes the need for washing or additional dyes, making it ideal for microplate readers.
- If your primary focus is absolute specificity to caspase‑3 over other executioner caspases: Supplement the DEVD linker construct with a second, mutated linker control (e.g., DEVA) that is cleaved poorly by caspase‑3, and titrate the inhibitor to calculate a selectivity window.
A well‑designed BRET2 reporter turns an elusive intracellular cleavage event into a clean, quantitative optical signal—giving you a direct window into the protease’s activity as it happens.
Summary Table:
| Component / Step | Construct Detail | Mechanism & Signal Impact |
|---|---|---|
| Basal Fusion Construct | GFP2 – DEVD Linker – Rluc | High 515/410 nm BRET2 ratio due to donor-acceptor proximity |
| Protease Cleavage Event | Caspase-3 cuts DEVD tetrapeptide | Separation of Rluc/GFP2 causes dose-dependent signal drop |
| Assay Specificity Check | Co-incubation with Ac-DEVD-CHO | Prevents cleavage, maintaining high BRET2 basal signal |
| Negative Control Design | Non-cleavable GFP2-Rluc fusion | Rules out false positives from aggregation or degradation |
Accelerate Your Bioassay Development with CamelBio
Building high-performance BRET2 reporter assays requires precise molecular design and reliable bioluminescent components. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Whether you are optimizing protease sensors, scaling high-throughput screening assays, or seeking custom technical guidance, our team is here to support your breakthrough.
Ready to elevate your assay performance? Contact CamelBio today to discuss your project requirements with our technical experts!